Book a demo

Cut patent&paper research from weeks to hours with PatSnap Eureka AI!

Try now

Immune-Mediated Neuropathy Pipeline — PatSnap Eureka

Immune-Mediated Neuropathy Pipeline — PatSnap Eureka
Neuropathy Drug Pipeline

Immune-Mediated Neuropathy Pipeline: FcRn & Complement Approaches in CIDP, GBS & MMN

Pathogenic autoantibodies targeting nodal and paranodal proteins drive CIDP, GBS, and MMN. A new generation of FcRn antagonists and complement inhibitors is challenging the non-specific standard of care — and defining the next wave of seropositive patient stratification.

Therapeutic Modality Activity in Immune-Mediated Neuropathy Pipeline: FcRn Antagonism 2 patents, Complement Inhibition (C5) 2 patents, Complement Inhibition (C2) 1 patent, BTK Inhibition 1 case report, IFN-beta 1 inactive patent, S1P Analogs 1 inactive patent Patent and literature activity by therapeutic modality for CIDP, GBS, and MMN, derived from PatSnap Eureka dataset analysis. FcRn antagonism (Immunovant) and complement inhibition (Alexion, argenx) represent the most active emerging modalities with active/pending patents as of 2025. FcRn Antagonism 2 active patents Complement (C5) 2 patents Complement (C2) 1 active patent BTK Inhibition Case report IFN-β / S1P Inactive Patent & literature activity (PatSnap Eureka dataset)
9%
Anti-NF155 IgG4 seroprevalence in CIDP (meta-analysis)
100%
Diagnostic specificity of anti-NF155 IgG4 in CIDP
~50%
MMN patients with anti-GM1 IgM antibodies
18%
Anti-NF155 positivity in Kyushu University consecutive cohort
Disease Biology

Autoantibody-Driven Peripheral Nerve Disorders: Shared Biology, Distinct Subtypes

Peripheral neuropathy drug discovery is increasingly driven by autoantibody serotyping. CIDP, GBS, and MMN represent a spectrum of immune-mediated peripheral nerve disorders in which both humoral and cellular immunity contribute to nerve injury, with relative contributions differing by disease subtype and patient serotype.

Nodal and paranodal autoantibodies are a prominent focus across retrieved patent and literature records. Antibodies against neurofascin-155 (NF155), neurofascin-186 (NF186), contactin-1 (CNTN1), contactin-associated protein 1 (Caspr1/CNTN1R), and pan-neurofascin epitopes have been identified in subsets of CIDP and GBS patients. These autoantibodies target proteins at the node of Ranvier, interfering with saltatory conduction and constituting a defined seropositive CIDP population with distinct clinical features and often suboptimal responses to standard IVIg therapy.

Anti-ganglioside antibodies (particularly anti-GM1 IgM) are detected in approximately 50% of MMN patients and are implicated in conduction block at nodes of Ranvier. In GBS, anti-ganglioside antibodies activating complement at axonal membranes underpin the acute motor axonal neuropathy (AMAN) variant. WHO recognizes GBS as a rapidly evolving condition requiring urgent clinical attention.

Anti-MAG IgM paraproteinemic neuropathy involves IgM antibodies against myelin-associated glycoprotein with complement deposition on the myelin sheath — a mechanism directly invoked in patent claims from Alexion Pharmaceuticals for complement inhibition. The IP analytics landscape for these indications is rapidly evolving.

A 2023 paper from International University of Health and Welfare, Fukuoka, identifies anti-LGI4 as a novel juxtaparanodal autoantibody in CIDP patients seronegative for anti-NF155 and anti-CNTN1, demonstrating ongoing discovery of new target antigens that may define further treatable subsets.

Key Molecular Targets
  • NF155 — IgG4 paranodal target; CIDP subtype marker
  • NF186 / Pan-neurofascin — IgG3 complement-fixing; severe disease
  • CNTN1 / Caspr1 — IgG4 seropositive CIDP subgroups
  • GM1 ganglioside — Anti-GM1 IgM in ~50% MMN patients
  • Complement C1q / C2 / C5 — Effector pathway targets
  • FcRn (FCGRT) — IgG recycling receptor; catabolism target
  • LGI4 — Novel juxtaparanodal target (2023 discovery)
  • MAG — IgM paraproteinemic neuropathy target
IgG4
Dominant subclass in anti-NF155 CIDP — does not fix complement
IgG3
Pan-neurofascin subtype — complement-fixing; high mortality
41
Seropositive patients in Ulm immunoadsorption cohort — 0 good responses
2022
Priority date for Immunovant anti-FcRn CIDP patents
Data Intelligence

Seroprevalence & Complement Target Coverage Across Indications

Key quantitative signals from the patent and literature dataset, visualised from retrieved records via PatSnap Eureka.

Anti-NF155 IgG4 Seroprevalence in CIDP Cohorts

Meta-analysis (China Medical University) reports 9% pooled sensitivity with 100% specificity; Kyushu University consecutive cohort shows 18% positivity — all uniformly IgG4 subclass.

Anti-NF155 IgG4 Seroprevalence in CIDP: Meta-analysis sensitivity 9%, Meta-analysis specificity 100%, Kyushu University cohort positivity 18%, Anti-GM1 IgM in MMN ~50% Seroprevalence data for anti-NF155 IgG4 antibodies in CIDP patient cohorts and anti-GM1 IgM in MMN, derived from patent and literature analysis via PatSnap Eureka. IgG4 subclass predominance has direct implications for FcRn versus complement therapeutic strategy selection. 100% 75% 50% 25% 9% Meta-analysis sensitivity 100% Meta-analysis specificity 18% Kyushu cohort positivity ~50% Anti-GM1 IgM in MMN

Complement Inhibition: Pathway Coverage by Target

Anti-C2 (argenx) blocks both classical and lectin pathways upstream; anti-C5 (Alexion) targets terminal MAC formation; anti-C1q (University of Glasgow) offers superior tissue specificity in ganglioside-rich motor nerves.

Complement Pathway Coverage by Inhibition Target: C5 inhibition (Alexion) covers GBS, CIDP, MMN, anti-MAG; C2 inhibition (argenx) covers MMN, CIDP, GBS via classical and lectin pathways; C1q inhibition (University of Glasgow) offers superior tissue specificity in AMAN-GBS Schematic of three complement inhibition intervention points in immune-mediated neuropathy, derived from patent and literature analysis via PatSnap Eureka. The upstream C2 target (argenx 2025 patent) provides the broadest pathway coverage, while C1q inhibition offers superior specificity at ganglioside-rich motor nerve nodes. Antigen-Ab Complex C1q Classical init. ← Anti-C1q (Glasgow) Lectin Pathway C2 Upstream branch ← Anti-C2 (argenx 2025) C5 Terminal/MAC ← Anti-C5 (Alexion) MAC / Nerve Injury C1q inhibition — superior tissue specificity (AMAN-GBS) C2 inhibition — classical + lectin coverage (argenx, 2025 EP) C5 inhibition — most clinically advanced; GBS, CIDP, MMN, anti-MAG Source: PatSnap Eureka patent & literature dataset · 2012–2025

Search the full CIDP, GBS & MMN patent landscape on PatSnap Eureka

Run a Live Pipeline Search
Therapeutic Modalities

Emerging Pipeline Approaches: FcRn, Complement, BTK, and Beyond

Six therapeutic modalities are active or emerging in this dataset, spanning patent-driven commercial entities and academic preclinical work. Standard-of-care IVIg/SCIg serves as the benchmark comparator.

Most IP-Active Modality

FcRn Antagonism (Anti-FcRn Antibodies)

Anti-FcRn antibodies block the neonatal Fc receptor, accelerating catabolism of all IgG subclasses including pathogenic anti-NF155, anti-CNTN1, and anti-GM1 autoantibodies. Patent analytics reveal Immunovant Sciences GmbH holds two active/pending IL-jurisdiction patents (2025) with a September 2022 priority date, specifically claiming anti-FcRn antibody methods for CIDP treatment. IgG4 subclass predominance in anti-NF155 CIDP means FcRn-mediated depletion is mechanistically more relevant than complement inhibition for this subtype, as IgG4 does not fix complement.

Immunovant Sciences GmbH · 2 patents · 2025
Most Patent-Dense Modality

Complement Pathway Inhibition (C5, C2, C1q)

Three distinct intervention points: Anti-C5 (Alexion) — active EP patent (2016) covering GBS, AMAN, CIDP, anti-MAG neuropathy via MAC prevention. Anti-C2 (argenx) — active EP patent (2025) blocking both classical and lectin pathways; explicitly names MMN, CIDP, and GBS. Anti-C1q (University of Glasgow) — preclinical AMAN mouse model data showing superior tissue specificity versus C5 inhibition at ganglioside-rich motor nerve nodes. The EPO portfolio for complement inhibitors in neuropathy spans 2012–2025.

Alexion · argenx · University of Glasgow
Emerging B-Cell Strategy

BTK Inhibition (Tirabrutinib)

A case report from Juntendo University School of Medicine describes successful treatment of rituximab-refractory anti-MAG neuropathy with tirabrutinib, a second-generation Bruton's tyrosine kinase (BTK) inhibitor, providing an early clinical signal for BTK inhibition in paraproteinemic neuropathy at 11 months of follow-up. Combined with the known role of B cells and plasma cells in generating IgG4 paranodal autoantibodies, BTK inhibition represents an emerging upstream strategy complementary to FcRn and complement approaches.

Juntendo University · 11-month sustained response
Phase 3 Benchmark

Subcutaneous Immunoglobulin (SCIg / IVIg)

IVIg and SCIg remain the standard of care against which emerging therapies are evaluated. The PATH trial (van Schaik et al., Lancet Neurology 2018), referenced in a Wayne State University appraisal, demonstrated that subcutaneous immunoglobulin is an effective maintenance therapy for CIDP. Multiple IVIg mechanisms are described: complement inhibition, FcγR saturation, anti-idiotypic antibody effects, and Fc-mediated receptor modulation. UMC Utrecht literature covers IVIg in MMN. Despite phase 3 efficacy, seropositive patients — particularly anti-NF155 IgG4 — characteristically fail IVIg.

PATH trial · Phase 3 · Wayne State / UMC Utrecht
Repurposing / Emerging

S1P Receptor Agonists & MS Disease-Modifying Therapies

FTY720 (fingolimod), an S1P receptor agonist depleting peripheral lymphocytes, demonstrated disease control in a chronic experimental autoimmune neuritis (c-EAN) rat model at the University of Strasbourg. However, fingolimod was not effective in the SAPP mouse model, highlighting model-dependent limitations. A University of Cologne review (2023) discusses repurposing MS DMTs — including natalizumab, ocrelizumab, and ofatumumab — for CIDP, citing pathogenesis homologies. Novartis AG holds an inactive 2012 IL patent on S1P-related immunosuppressant scaffolds for demyelinating peripheral neuropathy.

University of Strasbourg · Novartis (inactive) · Cologne 2023
Unmet Need Evidence

Apheresis / Immunoadsorption — Demonstrating the Gap

A University of Ulm clinical study of immunoadsorption (IA) and plasma exchange (PLEx) in seropositive inflammatory neuropathy found that, despite transient antibody suppression, no patients in a 41-patient cohort achieved a good response as rated by treating clinicians. This underscores the therapeutic gap that motivates FcRn antagonism and targeted complement inhibition as alternatives to non-specific antibody reduction strategies. The NIH/NINDS recognizes CIDP as an area of active therapeutic investigation.

University of Ulm · 41 patients · 0 good responses
PatSnap Eureka

Search the full FcRn and complement inhibitor patent landscape

Access assignee filings, priority dates, and claim-level analysis for CIDP, GBS, and MMN in one AI-powered search.

Analyse Modality Patents on Eureka
IP Landscape

Commercial Assignees: Patent Activity in CIDP, GBS & MMN

Innovation activity bifurcates between commercial patent-driven entities focused on FcRn and complement modalities, and academic literature-driven centres focused on disease biology and biomarker development.

Assignee Modality Target Indication(s) Patent Status Jurisdiction / Year
Immunovant Sciences GmbH (Basel, Switzerland) Anti-FcRn antibody CIDP Pending IL · 2025 (priority Sep 2022)
argenx BVBA (Ghent, Belgium) Anti-C2 complement antagonist MMN, CIDP, GBS, paraproteinemic neuropathies Active EP · 2025
Alexion Pharmaceuticals, Inc. (New Haven, USA) Anti-C5 antibody / complement inhibitor GBS, AMAN, CIDP, anti-MAG neuropathy Active EP · 2016
Alexion Pharmaceuticals, Inc. (New Haven, USA) Anti-C5 antibody / complement inhibitor Antibody-mediated neuropathies Inactive IL · 2012
KU Leuven / KU Leuven R&D (Leuven, Belgium) sNfL prognostic biomarker CIDP (therapy response / disease progression) Active EP · 2024
Biogen MA Inc. (Cambridge, USA) IFN-β therapeutics CIDP Inactive IL · 2006
Novartis AG (Basel, Switzerland) S1P-related immunosuppressants Demyelinating peripheral neuropathy Inactive IL · 2012
Vaccinex, Inc. (Rochester, USA) CXCL13-binding molecules Peripheral nerve regeneration (adjacent) Active JP · 2025
🔒
Unlock Full Assignee Claim Analysis
Access claim-level breakdowns, priority date timelines, and freedom-to-operate signals for every assignee in the CIDP/GBS/MMN patent landscape via PatSnap Eureka.
Claim scope maps Priority date chains FTO analysis + more
Access Full Patent Intelligence →

Map competitive IP positions across FcRn and complement modalities

PatSnap Eureka surfaces assignee landscapes, claim overlaps, and white-space opportunities for any neuropathy target.

Explore IP Landscape on Eureka
Translational Signals

Clinical & Translational Evidence: What the Dataset Reveals

Seven translational signals are identified across retrieved patent and literature records, spanning phase 3 benchmarks, IND-enabling preclinical data, and emerging biomarker evidence.

📋

Phase 3 SCIg Benchmark (PATH Trial)

The PATH trial (van Schaik et al., Lancet Neurology 2018), referenced in a Wayne State University appraisal, demonstrated that subcutaneous immunoglobulin is an effective maintenance therapy for CIDP, providing the phase 3 benchmark against which FcRn and complement candidates will be evaluated.

🔬

Anti-FcRn (Immunovant) in CIDP — Active Development

Two pending IL patents from Immunovant Sciences GmbH (priority September 2022) describe clinical methods of treating CIDP with anti-FcRn antibodies, including specific dosing and patient stratification strategies. Their pending status and recent priority date are consistent with ongoing clinical development, though no trial outcome data appear in the retrieved records.

🧬

Seropositive Patient Stratification for Trial Design

Multiple clinical cohort studies identify seropositive subgroups — anti-NF155 IgG4, anti-CNTN1 IgG4, and anti-pan-NF IgG3 — with defined treatment response profiles. Anti-NF155 IgG4 patients characteristically fail IVIg; anti-pan-NF IgG3 patients have high mortality. These findings directly inform patient selection for FcRn and complement trials.

📊

sNfL as Pharmacodynamic Biomarker

Retrospective and prospective clinical studies (Toyama University, KU Leuven, London National Hospital) demonstrate that serum neurofilament light chain (sNfL) levels fall with IVIg treatment in CIDP and correlate with disease activity. A KU Leuven EP patent claims sNfL for prognostic use in CIDP. This biomarker is positioned to serve as a pharmacodynamic endpoint in future FcRn and complement trials, potentially accelerating go/no-go decisions and reducing trial size requirements.

🔒
Unlock Remaining Translational Signals
Access C5 inhibition preclinical-to-IND evidence, BTK inhibition case data, and immunoadsorption failure analysis in seropositive cohorts.
C5 inhibition GBS evidence BTK tirabrutinib signal Ulm IA cohort data
Access Full Evidence on Eureka →
Strategic Implications

What the Pipeline Signals Mean for Drug Developers

FcRn antagonism is the most IP-active emerging modality in this dataset. Immunovant Sciences GmbH holds two pending patents specifically for anti-FcRn antibodies in CIDP with a 2022 priority date. argenx, with its existing FcRn antagonist efgartigimod, is simultaneously pursuing complement pathway IP (anti-C2). Organizations not holding FcRn IP in CIDP face a narrowing window for freedom-to-operate, particularly given the well-characterized seropositive subpopulations that can anchor clinical enrichment strategies.

Complement inhibition requires modality selection precision. Retrieved results reveal three distinct complement intervention points (C1q, C2, C5/C5a) with different efficacy profiles across GBS variants, CIDP, and MMN. Anti-C2 (argenx, active EP 2025) covers both classical and lectin pathways and represents a mechanistically broader claim than C5-only approaches. The patent analytics landscape suggests drug developers should evaluate upstream versus downstream complement targeting based on the specific autoantibody isotype and effector mechanism in each target indication.

The unmet need in MMN remains underaddressed. Whereas CIDP and GBS are the primary named indications in retrieved FcRn and complement patents, MMN — despite shared pathophysiology involving anti-GM1 complement-fixing IgM antibodies — is less prominently featured as a standalone indication. The argenx anti-C2 patent explicitly names MMN as a target; this represents a potential first-mover IP position for complement inhibition specifically in MMN, where more than 80% of patients respond to IVIg but slowly progressive axonal degeneration continues despite treatment.

The PatSnap customer network includes leading biopharma organizations using Eureka to identify white-space opportunities in autoimmune neurology. PatSnap's API enables programmatic access to the full patent and literature dataset for computational drug discovery teams. The EMA regulatory framework for orphan designations in rare neuropathies may provide development incentives for seropositive CIDP subpopulations.

Combination & Emerging Directions
  • FcRn + complement co-targeting — rational combination for IgG3/IgG1 complement-fixing paranodal disease
  • Upstream vs downstream complement — C1q tissue specificity vs C5 clinical maturity vs C2 pathway breadth
  • sNfL as PD biomarker — accelerates proof-of-concept in enriched seropositive populations
  • BTK inhibition — upstream B-cell strategy complementary to FcRn and complement
  • Anti-LGI4 discovery (2023) — continued antigen discovery in seronegative CIDP
  • TNF-α pathway — single-cell RNAseq (UCLA) identifies TNF-α as candidate target in Aire-deficient neuropathy model
Biomarker Readiness
Serum neurofilament light chain (sNfL) is validated across multiple academic papers and one active KU Leuven EP patent as a quantitative response biomarker in CIDP. Incorporating sNfL as a pharmacodynamic endpoint in phase 2 trials for FcRn and complement candidates could accelerate go/no-go decisions and reduce trial size requirements.
Search sNfL Biomarker Patents
Patent Timeline

Assignee Patent Activity: 2006–2025

Timeline of key patent filings across FcRn, complement, and immunomodulatory modalities, showing the shift from inactive early-stage approaches to active FcRn and upstream complement strategies.

Patent Filing Timeline by Assignee and Modality (2006–2025)

Active patents concentrate in 2024–2025 (Immunovant FcRn, argenx anti-C2, KU Leuven sNfL, Vaccinex CXCL13); inactive patents cluster in 2006–2012 (Biogen IFN-β, Novartis S1P, Alexion early C5). Alexion's 2016 EP anti-C5 patent remains active.

Patent Filing Timeline for Immune-Mediated Neuropathy: Biogen IFN-beta 2006 inactive, Novartis S1P 2012 inactive, Alexion C5 2012 inactive, Alexion C5 2016 active EP, argenx C2 2025 active EP, Immunovant FcRn 2025 active IL (priority 2022), KU Leuven sNfL 2024 active EP, Vaccinex CXCL13 2025 active JP Chronological patent filing activity for CIDP, GBS, and MMN from 2006 to 2025, derived from PatSnap Eureka dataset. The timeline shows a clear shift from inactive early immunomodulatory approaches toward active FcRn antagonism and upstream complement inhibition strategies in 2024–2025. 2006 2010 2014 2016 2020 2024 2025 Biogen IFN-β Alexion C5 (IL) Novartis S1P Alexion C5 EP ✓ KU Leuven sNfL EP ✓ argenx C2 EP ✓ Immunovant FcRn IL ✓ Inactive patent Active patent (complement) Active patent (FcRn) Active patent (biomarker)

Access the full assignee filing history and claim scope for any neuropathy target

Search Patent Timelines on Eureka
Frequently asked questions

Immune-Mediated Neuropathy Pipeline — Key Questions Answered

Still have questions? Let PatSnap Eureka search the neuropathy patent literature for you.

Ask PatSnap Eureka Your Pipeline Questions
PatSnap Eureka

Accelerate Your Immune-Mediated Neuropathy Drug Discovery

Join 18,000+ innovators already using PatSnap Eureka to map FcRn, complement, and autoantibody patent landscapes — and identify the white-space opportunities your pipeline needs.

References

  1. Autoantibodies Against the Node of Ranvier in Seropositive Chronic Inflammatory Demyelinating Polyneuropathy — University Hospital Würzburg, 2018
  2. Impact of Neurofascin on Chronic Inflammatory Demyelinating Polyneuropathy via Changing the Node of Ranvier Function: A Review — Karolinska Institute, 2021
  3. Association of neurofascin IgG4 and atypical chronic inflammatory demyelinating polyneuropathy: A systematic review and meta-analysis — First Affiliated Hospital of China Medical University, 2018
  4. Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy — Kyushu University, 2015
  5. Intravenous Immunoglobulin Treatment in Multifocal Motor Neuropathy — UMC Utrecht, 2010
  6. MMN: From Immunological Cross-Talk to Conduction Block — UMC Utrecht Brain Center Rudolf Magnus, 2014
  7. C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy — University of Glasgow, 2016
  8. Methods and compositions for the treatment of antibody mediated neuropathies — Alexion Pharmaceuticals, Inc., 2016 (EP active)
  9. Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies — argenx BVBA, 2025 (EP active)
  10. Emerging Role of C5 Complement Pathway in Peripheral Neuropathies: Current Treatments and Future Perspectives — Dompé Farmaceutici SpA, 2021
  11. Methods of treating chronic inflammatory demyelinating polyneuropathy using Anti-FcRn antibodies — Immunovant Sciences GmbH, 2025 (IL pending)
  12. Methods of treating chronic inflammatory demyelinating polyneuropathy using Anti-FcRn antibodies — Immunovant Sciences GmbH, 2025 (IL pending)
  13. Subcutaneous immunoglobulin proves to be an effective alternative to intravenous immunoglobulin in the treatment of chronic inflammatory demyelinating polyneuropathy — Wayne State University, 2020
  14. Prevention of Anti-HMGCR Immune-Mediated Necrotising Myopathy by C5 Complement Inhibition in a Humanised Mouse Model — UCB Pharma, 2022
  15. Anti-myelin-associated-glycoprotein neuropathy successfully treated with tirabrutinib — Juntendo University School of Medicine, 2022
  16. FTY720 controls disease severity and attenuates sciatic nerve damage in chronic experimental autoimmune neuritis — University of Strasbourg, 2019
  17. Immunoadsorption and Plasma Exchange in Seropositive and Seronegative Immune-Mediated Neuropathies — University of Ulm, 2020
  18. Guillain-Barré Syndrome — World Health Organization (WHO)
  19. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — NIH/NINDS
  20. European Patent Office (EPO) — Patent database and regulatory framework

All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.

Ask PatSnap Eureka
Ask PatSnap Eureka
AI innovation intelligence · always on
Ask anything about CIDP, GBS & MMN pipeline.
PatSnap Eureka searches patents and research to answer instantly.
Try asking
Powered by PatSnap Eureka